Our findings indicate that while ABCP demonstrated superior efficacy in aggressive NSCLC subtypes, specifically in patients with liver metastases, brain metastases, and EGFR mutations, this advantage was accompanied by a higher toxicity burden. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.